Kim Young-Sun, Rhim Hyunchul, Lim Hyo K, Choi Dongil, Lee Won Jae, Jeon Tae Yeon, Joh Jae Won, Kim Sung Joo
Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Kangnam-gu, Seoul, 135-710, Korea.
Ann Surg Oncol. 2008 Jul;15(7):1862-70. doi: 10.1245/s10434-008-9941-y. Epub 2008 May 8.
Intraoperative radiofrequency (RF) ablation with or without surgical resection currently plays one of important roles in modern hepatocellular carcinoma (HCC) therapy. We evaluated long-term follow-up results including prognostic factors of intraoperative RF ablation for HCC that was difficult to treat percutaneously.
A total of 133 patients (male, 22 female, mean age 55.8 years) underwent intraoperative RF ablations for 200 HCCs (follow-up period 3.0-79.7 months, median 22.3 months). Hepatic resection was also performed in 29 patients. Reasons for the intraoperative procedure included no safe electrode path (n = 59), excessive tumor burden (n = 41), nonvisualization of the HCC on ultrasonography (n = 20), and risk of collateral thermal damage to adjacent organs (n = 13). We evaluated the technique effectiveness rate at 1 month computed tomography (CT), cumulative local tumor progression rate, cumulative disease-free and overall survival rates, and complications. We also sought significant prognostic factors for overall survival.
The technique effectiveness at 1 month was 94.7% (126/133). The cumulative local tumor progression rates at 1 and 3 years were 4.9% and 8.8%, respectively. The cumulative disease-free and overall survival rates at 1, 3 and 5 years were 51.8%, 21.3%, and 16.0% and 92.3%, 72.6%, and 46.5%, respectively. Major complications occurred in nine patients (6.8%). Procedure-related mortality was 1.5% (2/133). The patients treated for recurrent HCC (P = 0.003) or with high serum alpha-fetoprotein levels (P = 0.009) had poor survival by multivariate analysis.
The results of this study showed that intraoperative radiofrequency ablation with or without hepatic resection is a safe and effective treatment for hepatocellular carcinoma in patients who are not candidates for the percutaneous approach.
术中射频(RF)消融联合或不联合手术切除目前在现代肝细胞癌(HCC)治疗中发挥着重要作用。我们评估了经皮难以治疗的HCC术中射频消融的长期随访结果,包括预后因素。
总共133例患者(男性111例,女性22例,平均年龄55.8岁)因200个HCC接受了术中射频消融(随访期3.0 - 79.7个月,中位数22.3个月)。29例患者还接受了肝切除术。术中操作的原因包括无安全电极路径(n = 59)、肿瘤负荷过大(n = 41)、超声检查未发现HCC(n = 20)以及对相邻器官造成侧支热损伤的风险(n = 13)。我们评估了1个月时计算机断层扫描(CT)的技术有效率、累积局部肿瘤进展率、累积无病生存率和总生存率以及并发症。我们还寻找总生存的显著预后因素。
1个月时的技术有效率为94.7%(126/133)。1年和3年时的累积局部肿瘤进展率分别为4.9%和8.8%。1年、3年和5年时的累积无病生存率和总生存率分别为51.8%、21.3%和16.0%以及92.3%、72.6%和46.5%。9例患者(6.8%)发生了主要并发症。与手术相关的死亡率为1.5%(2/133)。多因素分析显示,接受复发性HCC治疗的患者(P = 0.003)或血清甲胎蛋白水平高的患者(P = 0.009)生存较差。
本研究结果表明,术中射频消融联合或不联合肝切除术对于不适合经皮治疗的肝细胞癌患者是一种安全有效的治疗方法。